Get the content you want anytime you want.
REGISTER NOW | SIGN IN
IAS 2017 Conference

Select coverage from IAS 2017 Conference is included below:

Are There Any Risks Associated with Raltegravir HD?
Pedro Cahn, MD, describes the risk associated with raltegravir HD.
Who is the Target Population for Raltegravir HD?
Pedro Cahn, MD, explains who the target population is for raltegravir HD.
What Were the Results of the onceMRK Study at 96-Weeks Follow-Up?
Pedro Cahn, MD, shares the results found after 96-weeks of follow-up for the onceMRK Phase 3 clinical trial.
How Have Recent Advances Against HIV & AIDS Affected the Philanthropic Community?
Jake Glaser describes how recent advances against HIV & AIDS have affected the philanthropic community.
Fundraising for AIDS Programs in the 21st Century: Overcoming Challenges
Jake Glaser explains the challenges faced when fundraising for AIDS programs in the 21st century.
Who is Going to End the AIDS Epidemic?
Jake Glaser shares who he feels is going to end the AIDS epidemic.
What is Needed to Achieve an HIV & AIDS-Free World by 2030?
Jake Glaser shares what is needed to achieve the Fast-Track strategy to end the AIDS epidemic by 2030.
Who Will Benefit from the Darunavir Single-Tablet Regimen for HIV?
Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.
FEATURED
Big advances in treatment can